SEATTLE —There was no significant difference in cognitive outcomes for patients with retinopathy of prematurity treated with intravitreal bevacizumab compared with those treated with laser photocoagulation, according to a speaker here.
“The most important factor related to outcome was [gestational age] and the patient’s vision,” Wei-Chi Wu, MD, PhD, said at the American Society of Retina Specialists annual meeting.
According to Wu, intravitreal bevacizumab injections for ROP may cause less damage to the retina and offer a faster procedure, but there is concern that